GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 4th series registered coupon unguaranteed private convertible bond for gross proceeds of KRW 7,000,000,000 on May 11, 2018. The transaction will involve participation from Samsung Securities Co. Ltd., Investment Arm, will invest KRW 1,900,000,000, LCP-EN Secondary Fund, a fund managed by E&INVESTMENT INC., will invest KRW 1,500,000,000, and Solon New Technology Fund 1, will invest KRW 1,500,000. The bonds will carry a coupon of zero and have a yield to maturity of 3%. The bonds will be fully convertible into 1,515,151 common shares of the company at a fixed conversion price of KRW 4,620 per share between May 14, 2019 and December April 13, 2023. The bonds will mature on May 13, 2023. The subscription and payment date for the bonds is May 14, 2018. The transaction has been approved by the board of directors of the company.